Related Experiment Video
Updated: Apr 25, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Challenges in keeping pace with immunogenicity advances throughout the clinical development of a biological
1LGC, Newmarket Road, Fordham, Cambridgeshire, CB7 5WW, UK.
Progress in the assessment of immunogenicity over the past decade has been rapid; therapeutics in late-phase clinical studies today are subject to antidrug antibody analyses that have evolved considerably since the start of their clinical development. Data from bridging and direct ELISA methods used for the analysis of antidrug antibodies generated in response to an antibody therapeutic will be presented. The case study will highlight some of the challenges faced and the learning points gained from supporting immunogenicity analysis for these therapeutics.
Progress in the assessment of immunogenicity over the past decade has been rapid; therapeutics in late-phase clinical studies today are subject to antidrug antibody analyses that have evolved considerably since the start of their clinical development. Data from bridging and direct ELISA methods used for the analysis of antidrug antibodies generated in response to an antibody therapeutic will be presented. The case study will highlight some of the challenges faced and the learning points gained from supporting immunogenicity analysis for these therapeutics.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Preclinical Development: Overview
Microorganisms in Medicine and Therapeutics
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinical Trials: Overview

